Dr. Stewart
Medical Society Memberships:
- American Board of Ophthalmology
- American Medical Association
- Tennessee Ophthalmology Association
- American Society of Cataract and Refractive Surgeons
- American Academy of Ophthalmology
Research Experience:
- Bausch & Lomb – BLP 358-006: A randomized, double-masked, multicenter comparison of the aqueous humor concentration of Loteprednol Etabonate following administration of Bausch & Lomb Loteprednol Etabonate and Tobramycin ophthalmic suspension 0.5%/0.3% or Lotemax (Loteprednol Etabonate and Tobramycin ophthalmic suspension 0.5%) during routine cataract surgery
- ISTA Pharmaceuticals – ISTA-BR-CS001: A randomized, double-masked, multi-center study for the safety and efficacy of topical Bromfenac ophthalmic solution 0.1% Vs. placebo for treatment of ocular inflammation following cataract surgery
- Otsuka Maryland Research – Protocol 37E-03-201: A randomized, multi-center, double-masked, placebo controlled, parallel group, 26-week study of the safety and efficacy of Rebamipide ophthalmic suspension in the treatment of dry eye
- Alcon – C-04-14: A Clinical Evaluation of the Safety And Efficacy of StablEyz Intraocular Irrigating Solution Compared to BSS Plus for Use During Cataract Surgery and IOL implantation
- Alcon – C-04-17: A Multicenter, Double-Masked, Study of the Safety and Efficacy of Travatan® in patients with Open-Angle Glaucoma or Ocular Hypertension
- Novartis: A 24-week Randomized, double-blind, multicenter, Parallel-Group, Placebo-Controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions used twice daily in patients with moderate to severe keratoconjunctivitis sicca
- ISTA Pharmaceuticals: An evaluation of Vitrase® (ovine hyaluronidase injection, 150 USP units/mL) as an adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs prior to Ocular Surgery
- Alcon C-04-04: A study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Xalatan® and Timolol 0.5% Dosed Concomitantly in Patients Uncontrolled on Xalatan®
- Alcon: Maxidex identification of steroid responders to topical ophthalmic prednisolone
- Merck Protocol 137-00 IND# 36,642: A randomized, Multicenter, Double-Masked, Crossover Study Comparing the 24 hour Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combination Ophthalmic Solution to 0.5% Timolol Maleate Ophthalmic Solution in Patients with Open Angle Glaucoma or Ocular Hypertension
- ISTA Pharmaceuticals ISTA-TP-CPK01: Bio equivalent Study of Tobramycin and Prednisolone Acetate (0.3%/1.0%, ISTA) Ophthalmic suspension compared to PredForte® (1.0 Prednisolone acetate, Allergan ) Ophthalmic Suspension
- ISTA Pharmaceuticals ISTA-AH-CS01: Collection of Aqueous Humor from the anterior chamber during cataract surgery
- Alcon C-05-20: A 3-month clinical trial safety comparison of Nevanac 0.18% to Acular LS 0.4% and Vehicle following cataract surgery
- Alcon C-05-49: A one week comfort study of BID dosed Brinzolamide 1.0%/Timolol 0.5% Ophthalmic suspension compared to BID Dosed COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension
- Bausch & Lomb 434: A study to evaluate the clinical and microbial efficacay of 0.6% isv – 403 compared to Vigamox in the treatment of Bacterial conjunctivitis
- Merck Investigator Initiated Study: An Investigational comparison of Xalatan® versus Cosopt in “Persons of Hispanic Origin” (example: Mexican, Puerto Rican or Cuban) diagnosed with primary open angle glaucoma or ocular hypertension
- ISTA Pharmaceuticals: Investigator Intiated Study Protocol 100605 Phase 4, randomized, open label, patient controlled study to evaluate the efficacy of Xibrom (Bromfenac) compared with Econopred for the Treatment of Ocular Inflammation following Selective Laser Trabeculoplasty
- Alcon C-05-23: A Double-Masked, Parallel Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension
- ISTA Pharmaceuticals ISTA-BR-CS02: Efficacy and Safety of Topical Bromfenac Ophthalmic Solution Vs. Placebo for treatment of ocular inflammation and pain associated with cataract Surgery
- Pfizer: A 12-week, randomized, double-masked, parallel group comparison of Xalacom™ given in the evening, Xalatan® given in the evening and Timolol given in the morning in subjects with open angle glaucoma or ocular hypertension
- Allergan: Evaluation of the IOP lowering effect and tolerability of Bimatoprost 0.03% (Lumigan®) compared with Travoprost 0.004% (Travatan®) in patients with open angle glaucoma or ocular hypertension
- Alcon C-07-36 Investigator: Comparison of Safety and Duration of IOP-Lowering Efficacy of Three Alternative Travoprost Formulations to Vehicle and TRAVATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension
- Bausch & Lomb 526 Investigator: A randomized, double-masked, multicenter comparison of the aqueous humor concentration of Loteprednol Etabonate following administration of Bausch & Lomb Loteprednol Etabonate and Tobramycin ophthalmic suspension 0.5%/0.3% or Lotemax (Loteprednol Etabonate and Tobramycin ophthalmic suspension 0.5%) during routine cataract surgery
- ISTA Protocol CL-PKT-0415083-P Investigator: A multi-center, randomized, double-masked,bioequivalence study of T-Pred™ (Prednisolone Acetate 1% and Tobramycin 0.3% ophthalmic suspension) compared to Pred-Forte® (Prednisolone Acetate) 1% sterile ophthalmic suspension
Post-Doctoral Training:
Oculoplastic Surgery Fellowship
06/1996 to 07/1996
University of Texas Medical Branch
Department of Ophthalmology
301 University, Galveston, TX 77550
Ophthalmology Residency
06/1993 to 06/1996
University of Texas Medical Branch
Department of Ophthalmology
301 University, Galveston, TX 77550
Internal Medicine Internship
06/1992 to 06/93
University of Texas Medical Branch
Department of Internal Medicine
301 University, Galveston, TX 77550
Education:
American University
Plymouth, Montserrat
British West Indies
Medical School
University of Texas - Austin
Austin, Texas
Undergraduate Studies